26/120
1.1 / 5 stars
All 120 Win/Lose results shown below
HBIO Roast Me summary
HARVARD BIOSCIENCE INC (HBIO). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 24 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinHBIO / S&P 26.28% / 15.20% |
LoseHBIO / S&P -1.06% / 15.00% |
LoseHBIO / S&P HBIO unavailable / 50.40% |
| 2026-Q10/3 |
LoseHBIO / S&P -27.31% / -4.33% |
LoseHBIO / S&P -6.42% / 11.30% |
LoseHBIO / S&P HBIO unavailable / 27.70% |
| 2025-Q41/3 |
WinHBIO / S&P 52.27% / 2.65% |
LoseHBIO / S&P -8.06% / 9.00% |
LoseHBIO / S&P HBIO unavailable / 13.40% |
| 2025-Q30/3 |
LoseHBIO / S&P 0.00% / 8.12% |
LoseHBIO / S&P -10.60% / 4.61% |
LoseHBIO / S&P HBIO unavailable / 13.45% |
| 2025-Q20/3 |
LoseHBIO / S&P -22.81% / 10.94% |
LoseHBIO / S&P -12.24% / 4.83% |
LoseHBIO / S&P HBIO unavailable / 10.63% |
| 2025-Q10/3 |
LoseHBIO / S&P -72.99% / -4.27% |
LoseHBIO / S&P -14.41% / 4.98% |
LoseHBIO / S&P HBIO unavailable / 10.57% |
| 2024-Q40/3 |
LoseHBIO / S&P -21.56% / 2.41% |
LoseHBIO / S&P -16.14% / 5.25% |
LoseHBIO / S&P HBIO unavailable / 6.15% |
| 2024-Q30/3 |
LoseHBIO / S&P -5.61% / 5.89% |
LoseHBIO / S&P -13.15% / 5.89% |
LoseHBIO / S&P HBIO unavailable / 6.11% |
| 2024-Q20/3 |
LoseHBIO / S&P -32.78% / 4.28% |
LoseHBIO / S&P -11.36% / 5.38% |
LoseHBIO / S&P HBIO unavailable / 5.12% |
| 2024-Q10/3 |
LoseHBIO / S&P -20.75% / 10.56% |
LoseHBIO / S&P -6.76% / 5.71% |
LoseHBIO / S&P HBIO unavailable / 5.59% |
| 2023-Q41/3 |
WinHBIO / S&P 24.42% / 11.69% |
LoseHBIO / S&P -0.96% / 6.81% |
LoseHBIO / S&P HBIO unavailable / 7.78% |
| 2023-Q30/3 |
LoseHBIO / S&P -21.68% / -3.27% |
LoseHBIO / S&P -4.61% / 7.52% |
LoseHBIO / S&P HBIO unavailable / -5.03% |
| 2023-Q21/3 |
WinHBIO / S&P 30.71% / 8.74% |
LoseHBIO / S&P -5.49% / 9.50% |
LoseHBIO / S&P HBIO unavailable / -8.57% |
| 2023-Q11/3 |
WinHBIO / S&P 51.62% / 7.50% |
LoseHBIO / S&P -5.10% / 10.77% |
LoseHBIO / S&P HBIO unavailable / -15.69% |
| 2022-Q41/3 |
WinHBIO / S&P 8.20% / 7.56% |
LoseHBIO / S&P -4.68% / 11.88% |
LoseHBIO / S&P HBIO unavailable / -17.99% |
| 2022-Q30/3 |
LoseHBIO / S&P -28.89% / -4.88% |
LoseHBIO / S&P 0.97% / 13.47% |
LoseHBIO / S&P HBIO unavailable / -1.41% |
| 2022-Q20/3 |
LoseHBIO / S&P -42.03% / -16.10% |
LoseHBIO / S&P 8.54% / 13.71% |
LoseHBIO / S&P HBIO unavailable / 11.04% |
| 2022-Q10/3 |
LoseHBIO / S&P -11.91% / -4.60% |
LoseHBIO / S&P 14.60% / 15.97% |
LoseHBIO / S&P HBIO unavailable / 42.23% |
| 2021-Q41/3 |
LoseHBIO / S&P 1.00% / 11.03% |
WinHBIO / S&P 16.46% / 15.00% |
LoseHBIO / S&P HBIO unavailable / 96.40% |
| 2021-Q31/3 |
LoseHBIO / S&P -16.21% / 0.58% |
WinHBIO / S&P 14.44% / 10.77% |
LoseHBIO / S&P HBIO unavailable / 69.42% |
| 2021-Q21/3 |
WinHBIO / S&P 52.56% / 8.55% |
LoseHBIO / S&P 5.44% / 6.58% |
LoseHBIO / S&P HBIO unavailable / 51.81% |
| 2021-Q11/3 |
WinHBIO / S&P 27.27% / 6.17% |
LoseHBIO / S&P -5.75% / -1.06% |
LoseHBIO / S&P HBIO unavailable / 7.39% |
| 2020-Q41/3 |
WinHBIO / S&P 42.52% / 12.15% |
LoseHBIO / S&P -12.12% / -3.72% |
LoseHBIO / S&P HBIO unavailable / -33.42% |
| 2020-Q30/3 |
LoseHBIO / S&P -2.90% / 8.93% |
LoseHBIO / S&P -14.26% / -2.04% |
LoseHBIO / S&P HBIO unavailable / -27.10% |
| 2020-Q22/3 |
WinHBIO / S&P 40.27% / 20.54% |
LoseHBIO / S&P -12.31% / -0.46% |
WinHBIO / S&P -12.63% / -27.11% |
| 2020-Q11/3 |
LoseHBIO / S&P -27.54% / -19.60% |
LoseHBIO / S&P -8.57% / 3.47% |
WinHBIO / S&P -12.60% / -14.75% |
| 2019-Q40/3 |
LoseHBIO / S&P -0.97% / 9.07% |
LoseHBIO / S&P -3.81% / 5.36% |
LoseHBIO / S&P HBIO unavailable / 2.99% |
| 2019-Q32/3 |
WinHBIO / S&P 54.00% / 1.70% |
WinHBIO / S&P 9.67% / 5.02% |
LoseHBIO / S&P HBIO unavailable / 0.21% |
| 2019-Q21/3 |
LoseHBIO / S&P -53.60% / 4.30% |
WinHBIO / S&P 21.93% / 6.64% |
LoseHBIO / S&P HBIO unavailable / 8.65% |
| 2019-Q12/3 |
WinHBIO / S&P 35.53% / 13.65% |
WinHBIO / S&P 41.98% / 8.12% |
LoseHBIO / S&P HBIO unavailable / 14.29% |
| 2018-Q41/3 |
LoseHBIO / S&P -39.43% / -13.52% |
WinHBIO / S&P 56.02% / 9.05% |
LoseHBIO / S&P HBIO unavailable / 18.23% |
| 2018-Q31/3 |
LoseHBIO / S&P -1.87% / 7.71% |
WinHBIO / S&P 32.11% / 10.21% |
LoseHBIO / S&P HBIO unavailable / 19.06% |
| 2018-Q22/3 |
WinHBIO / S&P 7.00% / 3.43% |
WinHBIO / S&P 11.50% / 9.03% |
LoseHBIO / S&P HBIO unavailable / 14.46% |
| 2018-Q11/3 |
WinHBIO / S&P 51.52% / -0.76% |
LoseHBIO / S&P -10.00% / 7.68% |
LoseHBIO / S&P HBIO unavailable / 12.46% |
| 2017-Q40/3 |
LoseHBIO / S&P -12.00% / 6.64% |
LoseHBIO / S&P -25.94% / 7.03% |
LoseHBIO / S&P HBIO unavailable / 13.82% |
| 2017-Q31/3 |
WinHBIO / S&P 47.06% / 4.48% |
LoseHBIO / S&P -22.82% / 5.68% |
LoseHBIO / S&P HBIO unavailable / 17.57% |
| 2017-Q20/3 |
LoseHBIO / S&P -1.92% / 3.09% |
LoseHBIO / S&P -17.48% / 4.83% |
LoseHBIO / S&P HBIO unavailable / 17.74% |
| 2017-Q10/3 |
LoseHBIO / S&P -14.75% / 6.07% |
LoseHBIO / S&P -12.94% / 3.67% |
LoseHBIO / S&P HBIO unavailable / 13.32% |
| 2016-Q41/3 |
WinHBIO / S&P 12.13% / 3.82% |
LoseHBIO / S&P -3.81% / 2.09% |
LoseHBIO / S&P HBIO unavailable / 7.05% |
| 2016-Q30/3 |
LoseHBIO / S&P -4.90% / 3.85% |
LoseHBIO / S&P -3.78% / 0.20% |
LoseHBIO / S&P HBIO unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | HBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 59.80% | 20.78% |
| Annualized return | 59.80% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | HBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -90.36% | 83.14% |
| Annualized return | -37.37% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | HBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -70.41% | 319.30% |
| Annualized return | -11.46% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-24.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Quanterix Corp (QTRX) | United States | $0.150B | -1.65 |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |